Krebs Biochemicals & Industries Limited

8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034

CIN : L24110TG1991PLC013511

23rd May, 2015

To

The General Manager,
Listing Department,
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400001

Dear Sir,

Sub: Compliance with the SEBI Circular CIR/ISD/01/2015 dated 11th May, 2015
Ref: KREBS BIOCHEMICALS & INDUSTRIES LIMITED, Stock Code: 524518

We wish to confirm that our Company i.e., Krebs Biochemicals and Industries Limited

a. Formulated and published on its official website code of practices and procedures for fair disclosure of Unpublished Price Sensitive Information [under regulation 8 of SEBI (Prohibition of Insider Trading) Regulations, 2015]

b. Formulated code of conduct [under regulation 9 of SEBI (Prohibition of Insider Trading) Regulations, 2015]

This is for your information and records.

Thanking you

Yours sincerely
For **KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

AVINASH RAVI
Director & COO
DIN: 01616152

CC : National Stock Exchange of India Ltd
Exchange Plaza, 5th Flr, Plot No# C/1,
G Block, Bandra Kurla Complex,
Bandra (E) MUMBAI – 400 051

Tel : 0091-(0) 40-66037777 Fax : 0091-(0) 40-66037755
E-mail : krebs@krebsbiochem.com, marketing@krebsbiochem.com URL : www.krebsbiochem.com

Krebs Biochemicals & Industries Limited

8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034

CIN : L24110TG1991PLC013511

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

PRINCIPLES OF FAIR DISCLOSURE FOR PURPOSES OF CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION

1. Prompt public disclosure of unpublished price sensitive information that would impact price discovery no sooner than credible and concrete information comes into being in order to make such information generally available.

2. Uniform and universal dissemination of unpublished price sensitive unpublished price sensitive information to avoid selective disclosure.

3. Designation of a senior officer as a chief investor relations officer to deal with dissemination of information and disclosure of unpublished price sensitive information.

4. Prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently or otherwise to make such information generally available.

5. Appropriate and fair response to queries on news reports and requests for verification of market rumours by regulatory authorities.

6. Ensuring that information shared with analysts and research personnel is not unpublished price sensitive information.

7. Developing best practices to make transcripts or records of proceedings of meetings with analysts and other investor relations conferences on the official website to ensure official confirmation and documentation of disclosures made.

8. Handling of all unpublished price sensitive information on a need-to-know basis

Yours sincerely
For **KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

AVINASH RAVI
Director & COO
DIN: 01616152

CC : National Stock Exchange of India Ltd
Exchange Plaza, 5th Flr, Plot No# C/1,
G Block, Bandra Kurla Complex,
Bandra (E) MUMBAI – 400 051